Pages that link to "Q30364759"

The following pages link to Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. (Q30364759):

Displaying 45 items.

• Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques (Q27317212) (← links)
• Broad-Spectrum Drugs Against Viral Agents (Q27487859) (← links)
• A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome (Q28481488) (← links)
• Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands (Q28972540) (← links)
• Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. (Q30359335) (← links)
• Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans. (Q30365764) (← links)
• Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity (Q30370494) (← links)
• Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. (Q30375784) (← links)
• Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses (Q30377017) (← links)
• PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. (Q30381763) (← links)
• An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice (Q30390234) (← links)
• Intranasal administration of adjuvant‐combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus (Q30393453) (← links)
• Needle-free influenza vaccination. (Q30394326) (← links)
• Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine (Q30394396) (← links)
• Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16-17 November 2011. (Q30421294) (← links)
• Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia (Q30934025) (← links)
• Toll-like receptor agonists: are they good adjuvants? (Q34067537) (← links)
• TLR-based immune adjuvants. (Q34400322) (← links)
• Intranasal administration of dsRNA analog poly(I:C) induces interferon-α receptor-dependent accumulation of antigen experienced T cells in the airways (Q34510913) (← links)
• Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus (Q36059495) (← links)
• The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine (Q36497412) (← links)
• A unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses (Q36511199) (← links)
• Innate sensors of influenza virus: clues to developing better intranasal vaccines (Q37298227) (← links)
• Inhibition of dengue and chikungunya virus infections by RIG-I-mediated type I interferon-independent stimulation of the innate antiviral response. (Q37713902) (← links)
• Respective roles of TLR, RIG-I and NLRP3 in influenza virus infection and immunity: impact on vaccine design (Q37810600) (← links)
• Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations (Q37857257) (← links)
• Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. (Q37873932) (← links)
• Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective (Q38020309) (← links)
• Vaccine adjuvant uses of poly-IC and derivatives (Q38259510) (← links)
• Adenovirus-based vaccines against avian-origin H5N1 influenza viruses. (Q38283820) (← links)
• Potential approaches for more successful dendritic cell-based immunotherapy (Q38305650) (← links)
• Nucleic acid-based drugs against emerging zoonotic viruses (Q38591847) (← links)
• Advances in Antiviral Therapies Targeting Toll-like Receptors (Q38733975) (← links)
• TRIF-dependent TLR signaling, its functions in host defense and inflammation, and its potential as a therapeutic target (Q38830698) (← links)
• Functional and structural characteristics of secretory IgA antibodies elicited by mucosal vaccines against influenza virus (Q40093134) (← links)
• Consecutive inoculations of influenza virus vaccine and poly(I:C) protects mice against homologous and heterologous virus challenge (Q40362529) (← links)
• The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine (Q40820842) (← links)
• Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines (Q40998064) (← links)
• Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs. (Q41641768) (← links)
• Effect of pretreatment with toll-like receptor agonists in a mouse model of herpes simplex virus type 1 encephalitis (Q45392569) (← links)
• Induction of lung CD8+ T cell responses by consecutive inoculations of a poly(I:C) influenza vaccine. (Q47597577) (← links)
• Intranasal administration of inactivated avian influenza virus of H5N1 subtype vaccine-induced systemic immune response in chicken and mice. (Q55230928) (← links)
• Establishment of a novel safety assessment method for vaccine adjuvant development (Q57477472) (← links)
• Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under pre-existing anti-vector antibodies (Q84974121) (← links)
• Selection of adjuvants for vaccines targeting specific pathogens (Q90147842) (← links)